Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Penicillinase is a recombinant enzyme belonging to the beta-lactamase family, specifically designed to catalyze the hydrolysis of the beta-lactam ring in penicillin-type antibiotics. This enzymatic action effectively neutralizes the antibacterial properties of the drug. Produced by Zhuhai Gene-Biocon, it is marketed as a recombinant enzyme and active pharmaceutical ingredient (API) for use by other pharmaceutical and cosmetic manufacturers. While historically used as a therapeutic agent to treat severe penicillin-induced allergic reactions (anaphylaxis) by rapidly clearing the antibiotic from the systemic circulation, its contemporary application is primarily focused on laboratory diagnostics, microbiology testing, and as a reagent in pharmaceutical manufacturing processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on penicillinase.